Trial Profile
Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy with Pitavastatin in Coronary Artery Disease(REAL-CAD).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Oct 2023
Price :
$35
*
At a glance
- Drugs Pitavastatin (Primary)
- Indications Cardiovascular disorders; Coronary artery disease; Hypercholesterolaemia
- Focus Therapeutic Use
- Acronyms REAL-CAD
- 28 Aug 2023 Results (n=12,118) assessing Impact of worsening renal function (WRF) and baseline chronic kidney disease (CKD) on clinical outcomes in patients with chronic coronary syndromes presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology
- 14 Sep 2022 Results (n=11105) assessing the relationship between very low on-treatment low-density lipoprotein cholesterol (LDL-C) level and cardiovascular event risk is still unclear in patients receiving the same doses of statins, published in the Circulation Journal.
- 23 Jun 2021 Results of sub-study analysis assessing the effects on cardiovascular events in patients with stable coronary artery disease (CAD) and renal dysfunction, published in the American Heart Journal.